Search Results - "Goodman, A D"

Dose comparison trial of sustained-release fampridine in multiple sclerosis by GOODMAN, A. D, BROWN, T. R, COHEN, J. A, KRUPP, L. B, SCHAPIRO, R, SCHWID, S. R, COHEN, R, MARINUCCI, L. N, BLIGHT, A. R

“…To examine the efficacy and safety of three different doses of sustained-release fampridine in people with multiple sclerosis (MS). This multicenter,…”
Get full text

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate by Ford, C., Goodman, AD, Johnson, K., Kachuck, N., Lindsey, JW, Lisak, R., Luzzio, C., Myers, L., Panitch, H., Preiningerova, J., Pruitt, A., Rose, J., Rus, H., Wolinsky, J.

“…The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in relapsing—remitting multiple sclerosis (RRMS)…”
Get full text

GLANCE : Results of a phase 2, randomized, double-blind, placebo-controlled study by GOODMAN, A. D, ROSSMAN, H, PANZARA, M. A, SANDROCK, A. W, BAR-OR, A, MILLER, A, MILLER, D. H, SCHMIERER, K, LUBLIN, F, KHAN, O, BORMANN, N. M, YANG, M

“…To evaluate the safety and tolerability of natalizumab when added to glatiramer acetate (GA) in patients with relapsing multiple sclerosis. The primary outcome…”
Get full text

Rapid disease course in African Americans with multiple sclerosis by KISTER, I, CHAMOT, E, JUBELT, B, KRUPP, L, LENIHAN, M, LUBLIN, F, MIHAI, C, MILLER, A, MUNSCHAUER, F. E, PEREL, A. B, TETER, B. E, WEINSTOCK-GUTTMAN, B, BACON, J. H, ZIVADINOV, R, HERBERT, J, NIEWCZYK, P. M, DE GUZMAN, R. A, APATOFF, B, COYLE, P, GOODMAN, A. D, GOTTESMAN, M, GRANGER, C

“…To investigate utility of a Multiple Sclerosis Severity Scale (MSSS)-based classification system for comparing African American (AA) and white American (WA)…”
Get full text

What Does the Brain Do When You Fake It? An fMRI Study of Pantomimed and Real Grasping by Kroliczak, G, Cavina-Pratesi, C, Goodman, D. A, Culham, J. C

“…Canadian Institutes of Health Research Group in Action and Perception, Department of Psychology, University of Western Ontario, London, Canada Submitted 28…”
Get full text

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks by Morrow, SA, O'Connor, PW, Polman, CH, Goodman, AD, Kappos, L, Lublin, FD, Rudick, RA, Jurgensen, S, Paes, D, Forrestal, F, Benedict, RHB

“…Background and Objectives: Brief cognitive tests to monitor cognitive impairment in patients with multiple sclerosis (MS) are needed. Methods: Performance on…”
Get full text

Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study by Goodman, A.D., Cohen, J.A., Cross, A., Vollmer, T., Rizzo, M., Cohen, R., Marinucci, L., Blight, A.R.

“…Objective To determine the safety of sustained-release 4-aminopyridine in subjects with mutiple sclerosis (MS) and to examine dose-related efficacy up to 40 mg…”
Get full text

Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS by COHEN, J. A, IMREY, P. B, HUTTON, G. J, MANDELL, B. F, SCOTT, T. F, ZHANG, H, APPERSON-HANSEN, C, BECK, G. J, HOUGHTALING, P. L, KARAFA, M. T, STADTLER, M, CALABRESI, P. A, EDWARDS, K. R, EICKENHORST, T, FELTON, W. L, FISHER, E, FOX, R. J, GOODMAN, A. D, HARA-CLEAVER, C

“…To assess the safety, tolerability, and efficacy of interferon beta-1a (IFNbeta-1a) combined with methotrexate (MTX), i.v. methylprednisolone (IVMP), or both…”
Get full text

Expanded prediction equations of human sweat loss and water needs by Gonzalez, R. R, Cheuvront, S. N, Montain, S. J, Goodman, D. A, Blanchard, L. A, Berglund, L. G, Sawka, M. N

“…1 Biology Department, New Mexico State University, Las Cruces, New Mexico; and 2 United States Army Research Institute of Environmental Medicine, Natick,…”
Get full text

Quantitative functional measures in MS: What is a reliable change? by SCHWID, S. R, GOODMAN, A. D, MCDERMOTT, M. P, BEVER, C. F, COOK, S. D

“…As a first step toward understanding which changes should be considered as meaningful, the authors assessed the reliability of quantitative functional tests on…”
Get full text

United States and territory policies supporting maternal and neonatal transfer: review of transport and reimbursement by Okoroh, E M, Kroelinger, C D, Lasswell, S M, Goodman, D A, Williams, A M, Barfield, W D

“…Objective: Summarize policies that support maternal and neonatal transport among states and territories. Study Design: Systematic review of publicly available,…”
Get full text

Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS by COHEN, J. A, ROVARIS, M, GOODMAN, A. D, LADKANI, D, WYNN, D, FILIPPI, M

“…To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg daily vs the approved 20-mg formulation in relapsing-remitting multiple…”
Get full text

Quantitative assessment of motor fatigue and strength in MS by SCHWID, S. R, THORNTON, C. A, PANDYA, S, MANZUR, K. L, SANJAK, M, PETRIE, M. D, MCDERMOTT, M. P, GOODMAN, A. D

“…To determine the test-retest reliability of strength and fatigue measurements in patients with MS and in healthy control subjects, and to examine associations…”
Get full text

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis by SCHWID, S. R, PETRIE, M. D, MCDERMOTT, M. P, TIERNEY, D. S, MASON, D. H, GOODMAN, A. D

“…To evaluate the efficacy of 4-aminopyridine sustained release (4AP SR) (fampridine, EL-970) using quantitative measures of motor function in multiple sclerosis…”
Get full text

Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial by Johnson, K P, Brooks, B R, Ford, C C, Goodman, A D, Lisak, R P, Myers, L W, Pruitt, A A, Rizzo, M A, Rose, J W, Weiner, L P, Wolinsky, J S

“…The aim of this study was to assess the long-term safety and efficacy of glatiramer acetate (GA) for patients with multiple sclerosis (MS) who received active…”
Get full text

An open-label safety and drug interaction study of natalizumab (Antegren™) in combination with interferon-beta (Avonex®) in patients with multiple sclerosis by Vollmer, T L, Phillips, J T, Goodman, A D, Agius, M A, Libonati, M A, Giacchino, J L, Grundy, J S

“…In this open-label drug-interaction trial, we studied 38 patients with relapsing-remitting multiple sclerosis (MS) who received 3.0 or 6.0 mg/kg of natalizumab…”
Get full text

Avonex Combination Trial in relapsing—remitting MS: rationale, design and baseline data by Cohen, JA, Calabresi, PA, Chakraborty, S., Edwards, KR, Eickenhorst, T., Felton, WL, Fisher, E., Fox, RJ, Goodman, AD, Hara-Cleaver, C., Hutton, GJ, Imrey, PB, Ivancic, DM, Mandell, BF, Perryman, JE, Scott, TF, Skaramagas, TT, Zhang, H.

“…Objective To review the rationale, design and baseline data of the Avonex Combination Trial (ACT), an investigator-run study of intramuscular interferon…”
Get full text

Subclinical Slipped Capital Femoral Epiphysis. Relationship to Osteoarthrosis of the Hip by GOODMAN, DAVID A, FEIGHAN, JOHN E, SMITH, ANGELA D, LATIMER, BRUCE, BULY, ROBERT L, COOPERMAN, DANIEL R

“…We examined the femora of 2665 adult human skeletons from an osteological collection to determine the prevalence of post-slip morphology termed femoral…”
Get full text

The measurement of ambulatory impairment in multiple sclerosis by SCHWID, S. R, GOODMAN, A. D, MATTSON, D. H, MIHAI, C, DONOHOE, K. M, PETRIE, M. D, SCHEID, E. A, DUDMAN, J. T, MCDERMOTT, M. P

“…The objective of this study was to examine the relationships between continuous measures of ambulatory impairment in MS patients and their ordinal…”
Get full text

Benefit of interferon β-1a on MSFC progression in secondary progressive MS by COHEN, J. A, CUTTER, G. R, TSAO, E. C, WHITAKER, J. N, FISCHER, J. S, GOODMAN, A. D, HEIDENREICH, F. R, KOOIJMANS, M. F, SANDROCK, A. W, RUDICK, R. A, SIMON, J. H, SIMONIAN, N. A

Get full text